Germinated from assets acquired in 2003 from GSK, Affinium's antibacterial programs now include a broad base of intellectual property: issued and pending composition of matter patents on potent orally available small molecule inhibitors, genes, proteins, assays, crystal structures and combinations of FabInhibitors with known antibiotics. These assets represent a new class of antibiotics with a unique mechanism of action, targeting an unexploited pathway, bacterial fatty acid biosynthesis.
